Harwood Private Capital

Harwood Private Capital is a London-based private equity firm providing flexible structured capital to mid-market healthcare and pharmaceutical service companies. The firm sits within Harwood Capital Management’s broader asset management platform and benefits from longer-dated capital and a willingness to consider non-standard transaction structures. Healthcare exposure concentrates in tech-enabled care delivery and pharmaceutical services, reflecting Harwood’s preference for established, cash-generative businesses with clear scaling levers. It is not framed as an AI investor, and limited public information is available about named investment partners specifically attached to healthcare deals within Harwood Private Capital.

The firm invests at the Growth stage, with checks in the $5M to $25M range that fit mid-market businesses raising primary growth capital, financing acquisitions, or refinancing legacy capital structures. Geographic focus is the United Kingdom with selective European activity, and the firm engages directly with management teams or business owners considering partial liquidity or expansion capital. Transactions often include both equity and structured components, reflecting Harwood’s hybrid capital toolkit.

For founders and management teams, Harwood Private Capital is most relevant to operators of profitable healthcare and pharma services businesses considering a partnership with a flexible capital provider rather than a buyout. CEOs should expect rigorous diligence on financial performance, governance, and scaling plans, with active discussion of capital structure design. The firm is not suited to early-stage venture profiles, pre-revenue therapeutics, or founders unwilling to engage with structured deal terms. For mid-market UK healthcare services operators, it represents a flexible alternative to traditional buyout funds.